155 related articles for article (PubMed ID: 35237321)
1. Defining Diffuse Large B-Cell Lymphoma Immunotypes by CD8+ T Cells and Natural Killer Cells.
Qi J; Xu L; Huang D; He H; Yao J; Zhang J; Xu Y; Yang L
J Oncol; 2022; 2022():3168172. PubMed ID: 35237321
[TBL] [Abstract][Full Text] [Related]
2. A Machine Learning Model to Predict the Triple Negative Breast Cancer Immune Subtype.
Chen Z; Wang M; De Wilde RL; Feng R; Su M; Torres-de la Roche LA; Shi W
Front Immunol; 2021; 12():749459. PubMed ID: 34603338
[TBL] [Abstract][Full Text] [Related]
3. Machine-learning-based classification of diffuse large B-cell lymphoma patients by a 7-mRNA signature enriched with immune infiltration and cell cycle.
Zhuang X; Liu B; Long J; Wang H; Yu J; Ji X; Li J; Zhu N; Li L; Chen Y; Liu Z; Zhao S
Clin Transl Oncol; 2024 Apr; 26(4):936-950. PubMed ID: 37783922
[TBL] [Abstract][Full Text] [Related]
4. Gene set-based identification of two immune subtypes of diffuse large B cell lymphoma for guiding immune checkpoint blocking therapy.
Li Z; Duan Y; Ke Q; Wang M; Cen H; Zhu X
Front Genet; 2022; 13():1000460. PubMed ID: 36276947
[No Abstract] [Full Text] [Related]
5. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma.
Zhou M; Zhao H; Xu W; Bao S; Cheng L; Sun J
Mol Cancer; 2017 Jan; 16(1):16. PubMed ID: 28103885
[TBL] [Abstract][Full Text] [Related]
6. Artificial Neural Networks Predicted the Overall Survival and Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Pancancer Immune-Oncology Panel.
Carreras J; Hiraiwa S; Kikuti YY; Miyaoka M; Tomita S; Ikoma H; Ito A; Kondo Y; Roncador G; Garcia JF; Ando K; Hamoudi R; Nakamura N
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34945004
[TBL] [Abstract][Full Text] [Related]
7. International Prognostic Index-Based Immune Prognostic Model for Diffuse Large B-Cell Lymphoma.
Mu S; Shi D; Ai L; Fan F; Peng F; Sun C; Hu Y
Front Immunol; 2021; 12():732006. PubMed ID: 34745101
[TBL] [Abstract][Full Text] [Related]
8. Immunogenomic-Based Analysis of Hierarchical Clustering of Diffuse Large Cell Lymphoma.
Wang L; Yuan W; Li L; Shen Z; Geng Q; Zheng Y; Zhao J
J Immunol Res; 2022; 2022():9544827. PubMed ID: 35983077
[TBL] [Abstract][Full Text] [Related]
9. Immune scoring model based on immune cell infiltration to predict prognosis in diffuse large B-cell lymphoma.
Yang J; Yu L; Man J; Chen H; Zhou L; Zhao L
Cancer; 2023 Jan; 129(2):235-244. PubMed ID: 36345617
[TBL] [Abstract][Full Text] [Related]
10. Nasopharyngeal Carcinoma Subtype Discovery via Immune Cell Scores from Tumor Microenvironment.
Sun Y; Liu Y; Chu H
J Immunol Res; 2023; 2023():2242577. PubMed ID: 37274867
[TBL] [Abstract][Full Text] [Related]
11. Immune microenvironment-related gene mapping predicts immunochemotherapy response and prognosis in diffuse large B-cell lymphoma.
Chen W; Liang W; He Y; Liu C; Chen H; Lv P; Yao Y; Zhou H
Med Oncol; 2022 Jan; 39(4):44. PubMed ID: 35092504
[TBL] [Abstract][Full Text] [Related]
12. A prognostic gene model of immune cell infiltration in diffuse large B-cell lymphoma.
Zhou H; Zheng C; Huang DS
PeerJ; 2020; 8():e9658. PubMed ID: 32844062
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a five-gene signature associated with stromal infiltration for diffuse large B-cell lymphoma.
Nan YY; Zhang WJ; Huang DH; Li QY; Shi Y; Yang T; Liang XP; Xiao CY; Guo BL; Xiang Y
World J Clin Cases; 2021 Jun; 9(18):4585-4598. PubMed ID: 34222425
[TBL] [Abstract][Full Text] [Related]
14.
Sun J; Zhu X; Zhao Y; Zhou Q; Qi R; Liu H
Pharmgenomics Pers Med; 2021; 14():397-408. PubMed ID: 33833551
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive Characterization of Cachexia-Inducing Factors in Diffuse Large B-Cell Lymphoma Reveals a Molecular Subtype and a Prognosis-Related Signature.
Kuang Z; Li X; Liu R; Chen S; Tu J
Front Cell Dev Biol; 2021; 9():648856. PubMed ID: 34079795
[TBL] [Abstract][Full Text] [Related]
16. Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study.
Keane C; Vari F; Hertzberg M; Cao KA; Green MR; Han E; Seymour JF; Hicks RJ; Gill D; Crooks P; Gould C; Jones K; Griffiths LR; Talaulikar D; Jain S; Tobin J; Gandhi MK
Lancet Haematol; 2015 Oct; 2(10):e445-55. PubMed ID: 26686046
[TBL] [Abstract][Full Text] [Related]
17. A novel prognostic signature based on immune-related genes of diffuse large B-cell lymphoma.
Wu Z; Guan Q; Han X; Liu X; Li L; Qiu L; Qian Z; Zhou S; Wang X; Zhang H
Aging (Albany NY); 2021 Oct; 13(19):22947-22962. PubMed ID: 34610582
[TBL] [Abstract][Full Text] [Related]
18. ISPRF: a machine learning model to predict the immune subtype of kidney cancer samples by four genes.
Wang Z; Chen Z; Zhao H; Lin H; Wang J; Wang N; Li X; Ding D
Transl Androl Urol; 2021 Oct; 10(10):3773-3786. PubMed ID: 34804821
[TBL] [Abstract][Full Text] [Related]
19. Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies.
Xu-Monette ZY; Li J; Xia Y; Crossley B; Bremel RD; Miao Y; Xiao M; Snyder T; Manyam GC; Tan X; Zhang H; Visco C; Tzankov A; Dybkaer K; Bhagat G; Tam W; You H; Hsi ED; van Krieken JH; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; Winter JN; Medeiros JT; Xu B; Li Y; Kirsch I; Young KH
J Immunother Cancer; 2019 Oct; 7(1):272. PubMed ID: 31640780
[TBL] [Abstract][Full Text] [Related]
20. An integrated prognosis model of pharmacogenomic gene signature and clinical information for diffuse large B-cell lymphoma patients following CHOP-like chemotherapy.
Hu J; Xu J; Yu M; Gao Y; Liu R; Zhou H; Zhang W
J Transl Med; 2020 Mar; 18(1):144. PubMed ID: 32228625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
